(Q36092823)

12 August 2017

1 reference

title

Carcinogenesis, cancer therapy and chemoprevention (English)

1 reference

12 August 2017

1 reference

1

Blagosklonny MV

1 reference

12 August 2017

language of work or name

1 reference

1 June 2005

1 reference

Cell Death & Differentiation

12 August 2017

published in

1 reference

12 August 2017

volume

12

1 reference

12 August 2017

issue

6

1 reference

12 August 2017

page(s)

592-602

1 reference

Mutagenic and carcinogenic properties of platinum-based anticancer drugs

12 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401610

Selenium Supplementation and Secondary Prevention of Nonmelanoma Skin Cancer in a Randomized Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401610

Coupling apoptosis resistance to the cellular stress response: the IAP-Hsp90 connection in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401610

Multiple roles of the PI3K/PKB (Akt) pathway in cell cycle progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401610

Effect of epidermal growth factor receptor inhibitor on development of estrogen receptor-negative mammary tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401610

Mechanisms of apoptosis avoidance in cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401610

7 January 2021

The Hallmarks of Cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401610

7 January 2021

Proliferation, cell cycle and apoptosis in cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401610

7 January 2021

Apoptosis: a link between cancer genetics and chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401610

7 January 2021

A matter of life and death

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401610

7 January 2021

Genetic instabilities in human cancers

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401610

7 January 2021

Genetic instability and darwinian selection in tumours

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401610

7 January 2021

Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401610

7 January 2021

Improvement of chemotherapy efficacy by inactivation of a DNA-repair pathway

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401610

7 January 2021

Alkylation of DNA and its aftermath

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401610

7 January 2021

O6-alkylguanine-DNA alkyltransferase: role in carcinogenesis and chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401610

7 January 2021

Cancer after nuclear fallout: lessons from the Chernobyl accident

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401610

7 January 2021

The role of radioactive iodine in the treatment of advanced differentiated thyroid carcinoma.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401610

7 January 2021

Arsenic: carcinogen or cancer therapy?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401610

7 January 2021

How acute promyelocytic leukaemia revived arsenic

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401610

7 January 2021

Increased risk of malignant mullerian tumor of the uterus among women with breast cancer treated by tamoxifen

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401610

7 January 2021

Prevention of murine radiogenic thymic lymphomas by tumor necrosis factor or by marrow grafting

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401610

7 January 2021

Risk of malignant mixed mullerian tumors after tamoxifen therapy for breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401610

7 January 2021

12-O-Tetradecanoylphorbol-13-acetate (TPA)-induced increase in depressed white blood cell counts in patients treated with cytotoxic cancer chemotherapeutic drugs

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401610

7 January 2021

Effect of intravenous infusions of 12-O-tetradecanoylphorbol-13-acetate (TPA) in patients with myelocytic leukemia: preliminary studies on therapeutic efficacy and toxicity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401610

7 January 2021

Inhibitory effect of 12-O-tetradecanoylphorbol-13-acetate alone or in combination with all-trans-retinoic acid on the growth of LNCaP prostate tumors in immunodeficient mice

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401610

7 January 2021

The action of antitumor agents: A double-edged sword?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401610

7 January 2021

Increase therapy-related leukemia secondary to breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401610

7 January 2021

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401610

7 January 2021

Secondary acute myeloid leukemia in children previously treated with alkylating agents, intercalating topoisomerase II inhibitors, and irradiation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401610

7 January 2021

Tailoring cancer chemoprevention regimens to the individual

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401610

7 January 2021

Regional response leading to tumorigenesis after sulindac in small and large intestine of mice with Apc mutations

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401610

7 January 2021

Potential role of tamoxifen in prevention of breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401610

7 January 2021

Tamoxifen and toremifene treatment of breast cancer and risk of subsequent endometrial cancer: a population-based case-control study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401610

7 January 2021

Chemoprevention of Cancer - Focusing on Clinical Trials

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401610

7 January 2021

Neoplastic and antineoplastic effects of beta-carotene on colorectal adenoma recurrence: results of a randomized trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401610

7 January 2021

Cancer chemoprevention by dietary constituents: a tale of failure and promise

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401610

7 January 2021

A prospective study of aspirin use and the risk of pancreatic cancer in women

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401610

7 January 2021

Cancer genes and the pathways they control

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401610

7 January 2021

Strategies for reversing drug resistance

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401610

7 January 2021

The immature thymocyte is protected from N-methylnitrosourea-induced lymphoma by the human MGMT-CD2 transgene.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401610

7 January 2021

Overexpression of human O6-alkylguanine DNA alkyltransferase (AGT) prevents MNU induced lymphomas in heterozygous p53 deficient mice

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401610

7 January 2021

MGMT: its role in cancer aetiology and cancer therapeutics

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401610

7 January 2021

Requirement for p53 and p21 to sustain G2 arrest after DNA damage

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401610

7 January 2021

Principles of tumor suppression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401610

7 January 2021

Defects in the apoptotic machinery of cancer cells: role in drug resistance

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401610

7 January 2021

Apoptosis defects and chemotherapy resistance: molecular interaction maps and networks

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401610

7 January 2021

The TOR pathway: a target for cancer therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401610

7 January 2021

Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401610

7 January 2021

Putting the rap on Akt.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401610

7 January 2021

Apoptosis and genomic instability

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401610

7 January 2021

The multistep nature of cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401610

7 January 2021

Oncogenic resistance to growth-limiting conditions

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401610

7 January 2021

Normal and transformed human prokeratinocytes express divergent effects of a tumor promoter on cell cycle-mediated control of proliferation and differentiation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401610

7 January 2021

Cytostatic and apoptotic actions of TGF-beta in homeostasis and cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401610

7 January 2021

Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401610

7 January 2021

TGFbeta1 inhibits the formation of benign skin tumors, but enhances progression to invasive spindle carcinomas in transgenic mice

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401610

7 January 2021

TGF-beta switches from tumor suppressor to prometastatic factor in a model of breast cancer progression.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401610

7 January 2021

Development of resistance to cytotoxicity during aflatoxin carcinogenesis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401610

7 January 2021

Human mesothelioma cells and asbestos-exposed mesothelial cells are selectively resistant to amosite toxicity: a possible mechanism for tumor promotion by asbestos

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401610

7 January 2021

Differential effects of cigarette smoke condensate and its fractions on cultured normal and malignant human bronchial epithelial cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401610

7 January 2021

Human lung cancer and p53: the interplay between mutagenesis and selection

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401610

7 January 2021

Frequent clones of p53-mutated keratinocytes in normal human skin

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401610

7 January 2021

Cadmium adaptation in the lung - a double-edged sword?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401610

7 January 2021

Facilitation of tumour progression by cancer therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401610

7 January 2021

Selection with melphalan or paclitaxel (Taxol) yields variants with different patterns of multidrug resistance, integrin expression and in vitro invasiveness

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401610

7 January 2021

Enhanced in vitro invasiveness and drug resistance with altered gene expression patterns in a human lung carcinoma cell line after pulse selection with anticancer drugs.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401610

7 January 2021

A new superinvasive in vitro phenotype induced by selection of human breast carcinoma cells with the chemotherapeutic drugs paclitaxel and doxorubicin

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401610

7 January 2021

Human papillomavirus type 16-immortalized endocervical cells selected for resistance to cisplatin are malignantly transformed and have a multidrug resistance phenotype

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401610

7 January 2021

Molecular determinants of resistance to antiandrogen therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401610

7 January 2021

Tissue-selective therapy of cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401610

7 January 2021

The impact of clonal evolution on response to imatinib mesylate (STI571) in accelerated phase CML.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401610

7 January 2021

Mechanisms of resistance to STI571 in Philadelphia chromosome-associated leukemias

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401610

7 January 2021

BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401610

7 January 2021

Antiangiogenic therapy and tumor progression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401610

7 January 2021

The secondary leukemias: challenges and research directions

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401610

7 January 2021

Second cancers in survivors of childhood cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401610

7 January 2021

Second neoplasms after acute lymphoblastic leukemia in childhood.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401610

7 January 2021

Second malignant neoplasms in five-year survivors of childhood cancer: childhood cancer survivor study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401610

7 January 2021

Aberrant methylation of DAP-kinase in therapy-related acute myeloid leukemia and myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401610

7 January 2021

Radiation dose, chemotherapy and risk of osteosarcoma after solid tumours during childhood.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401610

7 January 2021

Radiotherapy, alkylating agents, and risk of bone cancer after childhood cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401610

7 January 2021

Secondary leukemias induced by topoisomerase-targeted drugs

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401610

7 January 2021

Percutaneous alcohol ablation for liver metastasis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401610

7 January 2021

Cytotoxicity of millimolar concentrations of ethanol on HepG2 human tumor cell line compared to normal rat hepatocytes in vitro

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401610

7 January 2021

Systemic treatment and liver transplantation for hepatocellular carcinoma: two ends of the therapeutic spectrum

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401610

7 January 2021

Sustained complete hematologic remission after administration of the tyrosine kinase inhibitor imatinib mesylate in a patient with refractory, secondary AML.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401610

7 January 2021

Ras mutation, irrespective of cell type and p53 status, determines a cell's destiny to undergo apoptosis by okadaic acid, an inhibitor of protein phosphatase 1 and 2A.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401610

7 January 2021

Induction of apoptosis and inhibition of papilloma formation may signal a new role for okadaic acid

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401610

7 January 2021

CHK1-regulated S-phase checkpoint response reduces camptothecin cytotoxicity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401610

7 January 2021

Apoptosis as a novel target for cancer chemoprevention

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401610

7 January 2021

Inhibition of carcinogenesis by tea

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401610

7 January 2021

Induction of apoptosis in fibroblasts by c-myc protein

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401610

7 January 2021

Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401610

7 January 2021

BCR/ABL regulates response to DNA damage: the role in resistance to genotoxic treatment and in genomic instability

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401610

7 January 2021

Disruption of p53 in human cancer cells alters the responses to therapeutic agents

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401610

7 January 2021

Selective killing of cancer cells by beta -lapachone: direct checkpoint activation as a strategy against cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401610

7 January 2021

Perspectives on the development of a molecularly targeted agent

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401610

7 January 2021

Cytogenetic and molecular genetic aspects of chronic myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401610

7 January 2021

Combinatorial chemoprevention of intestinal neoplasia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401610

7 January 2021

Cancer. Addiction to oncogenes--the Achilles heal of cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401610

7 January 2021

Treating cancer's kinase 'addiction'.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401610

7 January 2021

Lack of sustained regression of c-MYC-induced mammary adenocarcinomas following brief or prolonged MYC inactivation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401610

7 January 2021

Genomically complex lymphomas undergo sustained tumor regression upon MYC inactivation unless they acquire novel chromosomal translocations

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401610

7 January 2021

Increased expression of multidrug resistance related proteins Pgp, MRP1, and LRP/MVP occurs early in colorectal carcinogenesis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401610

7 January 2021

DNA repair protein MGMT protects against N-methyl-N-nitrosourea-induced conversion of benign into malignant tumors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401610

7 January 2021

Induced drug resistance inhibits selection of initiated cells and cancer development

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401610

7 January 2021

Opportunities and challenges in the development of kinase inhibitor therapy for cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401610

7 January 2021

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401610

7 January 2021

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401610

7 January 2021

Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401610

7 January 2021

Targeting cancer cells by exploiting their resistance

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401610

7 January 2021

Treatment with inhibitors of caspases, that are substrates of drug transporters, selectively permits chemotherapy-induced apoptosis in multidrug-resistant cells but protects normal cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401610

7 January 2021

Apoptosis-targeted therapies for cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401610

7 January 2021

Secondary leukemias in refractory germ cell tumor patients undergoing autologous stem-cell transplantation using high-dose etoposide

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401610

7 January 2021

Anti-apoptotic oncogenes prevent caspase-dependent and independent commitment for cell death

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401610

7 January 2021

Spontaneous reversion from blast to chronic phase after withdrawal of imatinib mesylate in a patient with chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401610

7 January 2021

Imatinib mesylate causes hypopigmentation in the skin

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401610

7 January 2021

Severe periorbital edema secondary to STI571 (Gleevec).

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401610

7 January 2021

Squamous cutaneous epithelial cell carcinoma in two CML patients with progressive disease under imatinib treatment

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401610

7 January 2021

Development of c-Kit-expressing small-cell lung cancer in a chronic myeloid leukemia patient during imatinib treatment

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401610

7 January 2021

Apoptosis and drug response

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401610

7 January 2021

Apoptosis and cancer drug targeting

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401610

7 January 2021

Apoptosis as a goal of cancer therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401610

7 January 2021

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401610

1 reference

7 January 2021

Apoptosis-regulating proteins as targets for drug discovery

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401610

7 January 2021

The attractive Achilles heel of germ cell tumours: an inherent sensitivity to apoptosis-inducing stimuli.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401610

7 January 2021

Alterations in the apoptotic machinery and their potential role in anticancer drug resistance

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401610

7 January 2021

Identifiers

DOI

10.1038/SJ.CDD.4401610

1 reference

12 August 2017

1 reference